Century Therapeutics, Inc. (IPSC) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 15.07M USD | Liabilities, Current |
| Cash and equivalents | 49.64M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $15.07M | $49.64M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $13.57M | $51.05M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $20.23M | $61.85M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $22.03M | $55.52M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $14.95M | $56.88M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $14.50M | $51.87M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $129.78M | $58.44M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $19.82M | $52.59M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $19.16M | $41.46M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $16.07M | $46.81M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $17.85M | $47.32M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $20.43M | $55.31M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $19.16M | $64.44M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $27.68M | $86.83M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $29.82M | $84.27M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $26.91M | $111.35M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $21.57M | $112.79M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $21.98M | $126.04M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $15.65M | $56.45M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $19.87M | $101.29M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $21.23M | $272.28M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $12.11M | $27.21M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |